Tirzepatide vs Semaglutide: Mounjaro vs Ozempic, head-to-head

Tirzepatide produces about 50% more weight loss than semaglutide. For a 90kg person, that gap translates to roughly 7 to 8 kg of additional weight loss over a year. The efficacy difference is real, consistent across multiple trials, and large enough to matter in practice.

Tirzepatide also tends to cause less nausea than semaglutide for most users, despite being more potent — the GIP co-agonism buffers some GLP-1 GI effects. People who stopped semaglutide because of nausea often do better on tirzepatide.

Semaglutide has a 5+ year longer track record. Ozempic has been in use since 2017 and has more real-world safety data than any other drug in this class. It is also significantly cheaper at both pharmacy and research-grade level.

Semaglutide is a single-agonist GLP-1 drug developed by Novo Nordisk. It mimics the GLP-1 hormone your gut releases after eating. FDA approved 2017 (Ozempic, diabetes), 2021 (Wegovy, obesity). Longest clinical history and largest real-world safety dataset of any drug in the class.

Tirzepatide is a dual-agonist drug targeting GLP-1 AND GIP, developed by Eli Lilly. GIP is involved in fat storage, insulin response, and energy balance. Activating both receptors simultaneously produces stronger weight loss and, surprisingly, better GI tolerability than GLP-1 alone. FDA approved 2022 (Mounjaro), 2023 (Zepbound).

STEP trials (semaglutide): at 2.4mg weekly, average 14.9% body weight loss over 68 weeks. Top performers reached 17.4%.

SURMOUNT trials (tirzepatide): at 15mg weekly, average 22.5% body weight loss over 72 weeks. Top performers reached 26.6%.

SURMOUNT-5 (head-to-head): tirzepatide outperformed semaglutide by approximately 8 percentage points at comparable study lengths.

Both drugs share the same serious risk warnings: thyroid cancer (in animal studies), pancreatitis, and gallbladder issues. Both can cause nausea, constipation, and fatigue during titration. The day-to-day tolerability difference favors tirzepatide for most users. See the GLP-1 side effects guide for management.

Switching is straightforward. Complete your last semaglutide dose on schedule, wait 7 days, then start tirzepatide at 2.5mg weekly and titrate upward. Do not skip the starting dose even if you were on a high semaglutide dose — the GIP receptor is new territory for your body and needs the gradual ramp.